Ipamorelin Peptide

Product Specifications

CAS: 170851-70-4

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.85 Da

Purity: 99%+ (verified by HPLC)

Appearance: White to off-white lyophilized powder

Form: Lyophilized (freeze-dried)

Classification: Growth Hormone Releasing Peptide (GHRP), Ghrelin Mimetic

Storage

Ipamorelin vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted ipamorelin peptide should be kept at -20°C for long-term storage or 2-8°C for short-term storage. Once reconstituted with bacteriostatic water, ipamorelin should be refrigerated at 2-8°C and used within 28-30 days for optimal stability. CJC-1295/ipamorelin storage temperature post-reconstitution follows the same standard: 2-8°C. Do not freeze reconstituted solutions. Always follow proper storage guidelines to maintain product integrity for research applications.

Solubility

Ipamorelin is freely soluble in bacteriostatic water and sterile saline. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

Ipamorelin is intended for research purposes only and is not approved for human use.

Ipamorelin Peptide Benefits: Selective GH Release Without Cortisol Elevation

• Ipamorelin acts via the GHS-R (ghrelin receptor / growth hormone secretagogue receptor) to trigger pulsatile GH release that closely mirrors natural secretion patterns. Its selectivity for GH over other pituitary hormones is the most studied and commercially significant characteristic of the ipamorelin peptide.
• Landmark preclinical research confirmed that ipamorelin produced a dose-dependent GH pulse in rats comparable in magnitude to GHRP-6 and GHRP-2, while causing no statistically significant increase in ACTH, cortisol, aldosterone, or prolactin even at doses up to 500 mcg/kg body weight.
• Ipamorelin side effects in preclinical models have been notably limited compared to other GHRPs. The absence of cortisol and prolactin elevation distinguishes ipamorelin peptide from earlier secretagogues and makes it a subject of interest for long-duration research protocols.
• Ipamorelin vs sermorelin: where sermorelin acts on GHRH receptors to stimulate GH secretion, ipamorelin acts on the ghrelin receptor with a distinct selectivity profile. Research identifies the two as complementary mechanisms, and their combination is studied for additive effects on growth hormone release.

CJC-1295 Ipamorelin: Synergistic Growth Hormone Release Research

• The CJC-1295 ipamorelin combination is one of the most researched GHRP/GHRH pairings in preclinical GH science. CJC 1295 acts on the GHRH receptor while ipamorelin acts on the GHS-R, meaning co-administration simultaneously stimulates the somatotropic axis from two distinct and complementary receptor targets.
• Research on GHRP and GHRH co-administration demonstrates a synergistic GH release that substantially exceeds what either compound produces independently. The dual-receptor mechanism underpins the scientific rationale for the CJC 1295 ipamorelin combination in modern peptide research.
• CJC 1295 ipamorelin dosage in preclinical research typically employs matched concentrations of both peptides administered together via subcutaneous injection, targeting GH secretion, body composition, and recovery endpoints.
• CJC 1295 ipamorelin shelf life after reconstitution follows standard peptide storage guidelines. Reconstituted solutions stored at 2-8°C should be used within 28-30 days. When preparing a CJC 1295 ipamorelin bacteriostatic water mix, use gentle swirling rather than shaking to preserve peptide integrity.

Ipamorelin Benefits for Bone Growth and Body Composition

• Preclinical studies in young rats show ipamorelin significantly stimulates longitudinal bone growth in a dose-dependent manner, producing measurable increases in tibia length and body weight over 2-week research periods. Effects are mediated through downstream GH and IGF-1 signaling.
• Ipamorelin peptide benefits in body composition research include increases in lean tissue mass consistent with GH-driven anabolic signaling, with growth gains attributed to lean mass increases rather than fat accumulation in treated research subjects.
• Ipamorelin dosage for bone growth research in animal models has been effective at 1-10 mcg/kg, with dose-dependent responses observed at the lower end of the range studied and effects comparable to exogenous GH treatment in matched controls.
• Ipamorelin before and after comparisons in controlled preclinical studies show statistically significant improvements in bone mineral content markers and lean mass, positioning the compound as an active area of GH secretagogue and skeletal biology research.

Ipamorelin Dosage for Research

Ipamorelin dosage per day used in preclinical research typically ranges from 1 to 10 micrograms per kilogram of body weight, administered once or twice daily. Ipamorelin has a short plasma half-life of approximately 2 hours, which shapes ipamorelin dosing protocols designed to replicate pulsatile GH secretion patterns. Common protocols in published literature include:

• Subcutaneous injection: 1-10 mcg/kg body weight, once to twice daily, used in bone growth and body composition models.
• Intraperitoneal injection: Comparable dosing used in metabolic and systemic GH secretion studies.
• CJC-1295 ipamorelin dosage (combination): Matched concentrations of both peptides administered together, leveraging synergistic GH release from complementary receptor targets.

Ipamorelin dosage and timing in research protocols often aligns administration with periods of fasting or rest cycles to maximize GH pulse amplitude, consistent with the natural relationship between feeding state and GH secretion dynamics.

Research Protocol Notes

Ipamorelin is supplied as a lyophilized (freeze-dried) powder to ensure stability during transport and storage. For research use, the peptide must be reconstituted using bacteriostatic water or sterile saline. Introduce the solvent slowly down the inside wall of the vial and gently swirl to dissolve. Do not shake or vortex the solution. CJC-1295/ipamorelin storage temperature post-reconstitution should be maintained at 2-8°C and used within 28-30 days for optimal peptide stability. Unreconstituted ipamorelin peptide should be kept at -20°C for long-term storage. When combining in a CJC 1295 ipamorelin bacteriostatic water mix, maintain the same storage and handling standards for both peptides.